Relative risks—including 95% confidence intervals (CI) and number of observed cancers—of solid cancers in the Early Arthritis RA cohort and in the TNF antagonist RA cohort, stratified by time since diagnosis of RA (Early Arthritis RA cohort) and time since start of TNF antagonist treatment (TNF antagonist RA cohort), respectively
| Cancer site (ICD) | <1 year | 1–2 years | 3+ years | |||
|---|---|---|---|---|---|---|
| No | SIR (95% CI) | No | SIR (95% CI) | No | SIR (95% CI) | |
| Relative risks compared with the general Swedish population adjusting for age, sex, and calendar period. | ||||||
| Early arthritis | ||||||
| All solid | 44 | 1.4 (1.1 to 1.9) | 55 | 1.1 (0.9 to 1.5) | 39 | 0.8 (0.6 to 1.2) |
| Colorectal | 5 | 1.3 (0.4 to 3.1) | 8 | 1.3 (0.6 to 2.5) | 5 | 0.8 (0.3 to 2.0) |
| Hepatobiliary | 0 | 0.0 (0.0 to 5.5) | 3 | 2.8 (0.6 to 8.3) | 2 | 2.1 (0.3 to 7.5) |
| Lung | 9 | 3.8 (1.8 to 7.3) | 6 | 1.6 (0.6 to 3.5) | 8 | 2.3 (1.0 to 4.6) |
| Breast | 4 | 0.7 (0.2 to 1.8) | 6 | 0.7 (0.2 to 1.5) | 3 | 0.4 (0.1 to 1.0) |
| Prostate | 11 | 2.3 (1.2 to 4.1) | 12 | 1.5 (0.8 to 2.7) | 9 | 1.2 (0.6 to 2.3) |
| Melanoma | 1 | 0.9 (0.0 to 4.9) | 3 | 1.7 (0.4 to 4.9) | 0.0 (0.0 to 2.2) | |
| Non-melanoma skin | 0 | 0.0 (0.0 to 2.2) | 2 | 0.7 (0.1 to 2.5) | 3 | 1.0 (0.2 to 2.9) |
| TNF antagonist | ||||||
| All solid | 25 | 1.0 (0.6 to 1.5) | 32 | 0.9 (0.6 to 1.3) | 10 | 0.8 (0.4 to 1.6) |
| Colorectal | 2 | 0.7 (0.1 to 2.6) | 8 | 2.0 (0.8 to 4.0) | 0 | 0.0 (0.0 to 2.8) |
| Hepatobiliary | 0 | 0.0 (0.0 to 7.7) | 1 | 1.5 (0.0 to 8.4) | 0 | 0.0 (0.0 to 17) |
| Lung | 5 | 2.6 (0.8 to 6.0) | 3 | 1.1 (0.2 to 3.2) | 2 | 2.3 (0.3 to 8.2) |
| Breast | 4 | 0.6 (0.2 to 1.6) | 3 | 0.3 (0.1 to 1.0) | 1 | 0.3 (0.0 to 1.9) |
| Prostate | 3 | 1.1 (0.2 to 3.3) | 3 | 0.7 (0.1 to 2.2) | 2 | 1.5 (0.2 to 5.4) |
| Melanoma | 0 | 0.0 (0.0 to 3.5) | 1 | 0.7 (0.0 to 3.8) | 0 | 0.0 (0.0 to 7.7) |
| Non-melanoma skin | 5 | 4.9 (1.6 to 11) | 5 | 3.3 (1.1 to 7.8) | 1 | 2.0 (0.1 to 11) |